AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29410385 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy control group (10 subjects)
Number of subjects: 20
Study 29410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight history trajectories (recently overweight, always overweight, steady-gain-obese)
Number of subjects: 221
Study 29410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent being overweight and current weight
Number of subjects: 221
Study 29410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about child weight
Number of subjects: 221
Study 29410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern for child weight and mothers' body guilt
Number of subjects: 221
Study 29410786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling letter intervention at month 1, 3, and 4
Number of subjects: 175
Study 29410786 — intervention group
Group type: COMPARATOR
Intervention: Repeated assessments of PA and ST
Number of subjects: 175
Study 29410955 — intervention group
Group type: EXPERIMENTAL
Intervention: 30g of prebiotics
Number of subjects: 0
Study 29410955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29411318 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab biosimilars
Number of subjects: 0
Study 29411318 — intervention group
Group type: COMPARATOR
Intervention: Substitution policies for biosimilars
Number of subjects: 0
Study 29411338 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion safety intervention bundle
Number of subjects: 840
Study 29412457 — intervention group
Group type: EXPERIMENTAL
Intervention: CRIS classifier
Number of subjects: 543
Study 29412457 — intervention group
Group type: COMPARATOR
Intervention: CMS classification
Number of subjects: 543
Study 29412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Acting β-Agonist/Inhaled Corticosteroid
Number of subjects: 0
Study 29412688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29412784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) added to radiotherapy plus temozolomide (RT+TMZ)
Number of subjects: 0
Study 29412784 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy plus temozolomide (RT+TMZ)
Number of subjects: 0
Study 29413039 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29413142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attention bias modification (ABM) training (n = 40)
Number of subjects: 84
Study 29413142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attention bias modification (ABM) training (n = 15)
Number of subjects: 84
Study 29413142 — intervention group
Group type: COMPARATOR
Intervention: Placebo protocol (n = 41)
Number of subjects: 84
Study 29413360 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased n-3 EPA+DHA with low n-6 linoleic acid (H3 L6)
Number of subjects: 153
Study 29413360 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased n-3 EPA+DHA with usual US dietary intake of n-6 linoleic acid (H3 H6)
Number of subjects: 153
Study 29413360 — intervention group
Group type: COMPARATOR
Intervention: Usual US dietary content of n-3 and n-6 fatty acids (L3 H6)
Number of subjects: 153
Study 29413510 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning symptoms
Number of subjects: 734
Study 29413510 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased symptoms
Number of subjects: 734
Study 29413684 — intervention group
Group type: EXPERIMENTAL
Intervention: HER family inhibitors (trastuzumab, lapatinib, afatinib)
Number of subjects: 31
Study 29413684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (lapatinib or afatinib)
Number of subjects: 31
Study 29413684 — intervention group
Group type: COMPARATOR
Intervention: Other molecularly targeted agents (mTOR, PI3K, NOTCH inhibitors, chemotherapy)
Number of subjects: 31
Study 29414920 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Left Atrial Appendage Closure (LAAC)
Number of subjects: 44
Study 29414995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus placebo
Number of subjects: 24
Study 29414995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton plus placebo
Number of subjects: 24
Study 29414995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29414995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24
Study 29414995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 24
Study 29414995 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment cohorts
Number of subjects: 24
Study 29415190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily alone (days 1-4)
Number of subjects: 4
Study 29415190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily with isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19)
Number of subjects: 4
Study 29415190 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and rifapentine (days 5-19)
Number of subjects: 4
Study 29415190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine and 25-desacetyl rifapentine (day 19)
Number of subjects: 4
Study 29415580 — intervention group
Group type: EXPERIMENTAL
Intervention: 20:1 cafedrine/theodrenaline
Number of subjects: 0
Study 29415580 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0
Study 29415760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Recovery Program (m-CCRP)
Number of subjects: 620
Study 29415760 — intervention group
Group type: COMPARATOR
Intervention: Attention control (printed material and telephone reminders)
Number of subjects: 620
Study 29415831 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min steady state (SS) criterion
Number of subjects: 68
Study 29415831 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min steady state (SS) criterion
Number of subjects: 68
Study 29415831 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SS criteria
Number of subjects: 68
Study 29415831 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min SS vs 5 min SS
Number of subjects: 68
Study 29415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl exposure (positive toxicology test)
Number of subjects: 231
Study 29415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin use
Number of subjects: 231
Study 29415853 — intervention group
Group type: COMPARATOR
Intervention: Non-heroin opioids use
Number of subjects: 231
Study 29415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief about fentanyl exposure
Number of subjects: 231
Study 29415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of negative test results
Number of subjects: 231
Study 29415853 — intervention group
Group type: EXPERIMENTAL
Intervention: Never exposed to fentanyl
Number of subjects: 231
Study 29415874 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE) imaging using the Cystoflex UHD-R probe in bladder study (60 patients)
Number of subjects: 85
Study 29415874 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE) imaging during ureterorenoscopy in upper urinary tract study (25 patients)
Number of subjects: 85
Study 29416368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutriage day cream (morning application)
Number of subjects: 22
Study 29416368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutriage night cream (evening application)
Number of subjects: 22
Study 29416652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4, along with HD-MTX 3.5g/m2, vincristine, procarbazine, cytarabine, and dexamethasone taper.
Number of subjects: 26
Study 29416870 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based mind-body (CBMB) intervention
Number of subjects: 75
Study 29416870 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 75
Study 29416870 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 75
Study 29416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower (telemedicine-based intra-operative clinical support system)
Number of subjects: 0
Study 29416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I testing (think-aloud protocol analyses)
Number of subjects: 0
Study 29416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II testing (qualitative and quantitative in situ usability and feasibility analysis)
Number of subjects: 0
Study 29416872 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prompts for falls, dehydration, and pulmonary aspiration
Number of subjects: 0
Study 29416872 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prompts
Number of subjects: 0
Study 29416986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m²) in combination with doxorubicin and cyclophosphamide (CAP regimen)
Number of subjects: 41
Study 29416986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin in association with doxorubicin and cyclophosphamide
Number of subjects: 41
Study 29417092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 10 hours of treatment
Number of subjects: 30
Study 29417092 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (various sedation methods)
Number of subjects: 30
Study 29417092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 30
Study 29417310 — intervention group
Group type: EXPERIMENTAL
Intervention: First-void urine samples
Number of subjects: 110
Study 29417310 — intervention group
Group type: COMPARATOR
Intervention: Cervical samples
Number of subjects: 110
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily with background MTX
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily with background GC
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib without MTX, initiated MTX
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib without GC, initiated GC
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib with MTX/GC discontinuation
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib with MTX initiation
Number of subjects: 3030
Study 29417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib with GC initiation
Number of subjects: 3030
Study 29419390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of ApoA1
Number of subjects: 14884
Study 29419390 — intervention group
Group type: COMPARATOR
Intervention: Composite ischemic outcome (ischemic stroke, systemic embolism, myocardial infarction, and cardiovascular death)
Number of subjects: 14884
Study 29419425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (dose escalation)
Number of subjects: 0
Study 29419434 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sequencing and flow cytometric characterization
Number of subjects: 0
Study 29419698 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) based approach for the detection of relevant infecting organisms
Number of subjects: 0
Study 29419698 — intervention group
Group type: COMPARATOR
Intervention: Standard (culture-based) microbiological diagnostics
Number of subjects: 0
Study 29419698 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based approach
Number of subjects: 0
Study 29420116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV7)
Number of subjects: 24
Study 29420116 — intervention group
Group type: COMPARATOR
Intervention: Immunocompetent controls
Number of subjects: 24
Study 29420218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low neighborhood socioeconomic status (SES)
Number of subjects: 525
Study 29420218 — intervention group
Group type: COMPARATOR
Intervention: Middle neighborhood socioeconomic status (SES)
Number of subjects: 525
Study 29420218 — intervention group
Group type: COMPARATOR
Intervention: High neighborhood socioeconomic status (SES)
Number of subjects: 525
Study 29420335 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 0
Study 29420335 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 0
Study 29420341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 778
Study 29420341 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial cohort (patients with exclusion criteria for enrollment into current interventional trials)
Number of subjects: 778
Study 29420395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 157
Study 29420395 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 157
Study 29420395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 29420467 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (pan-HER kinase inhibitor)
Number of subjects: 0
Study 29420708 — intervention group
Group type: EXPERIMENTAL
Intervention: S4 cells in females
Number of subjects: 100
Study 29420708 — intervention group
Group type: EXPERIMENTAL
Intervention: S7 cells
Number of subjects: 100
Study 29420708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 100
Study 29420708 — intervention group
Group type: EXPERIMENTAL
Intervention: S4 cells
Number of subjects: 100
Study 29420795 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy in younger patients (<50 years)
Number of subjects: 419
Study 29420795 — intervention group
Group type: COMPARATOR
Intervention: Opioid therapy in older patients (50-64 years)
Number of subjects: 419
Study 29420795 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy in younger and older patients
Number of subjects: 419
Study 29421016 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred invasive strategy
Number of subjects: 696
Study 29421016 — intervention group
Group type: COMPARATOR
Intervention: Early invasive strategy
Number of subjects: 696
Study 29421314 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intervention high-fat food cravings
Number of subjects: 32
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intervention fast-food cravings
Number of subjects: 32
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Post- vs. pre-intervention change in sweet cravings
Number of subjects: 32
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Post- vs. pre-intervention change in fast food cravings
Number of subjects: 32
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cravings for starchy food
Number of subjects: 32
Study 29421336 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in overall food cravings
Number of subjects: 32
Study 29421959 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioseal® closure device with early ambulation at 20 min after deployment
Number of subjects: 29
Study 29421959 — intervention group
Group type: COMPARATOR
Intervention: Conventional care with prolonged bed rest of 2-3 hours
Number of subjects: 29
Study 29421974 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Leisure-Time Activity Categorical Item (L-Cat)
Number of subjects: 301
Study 29421974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Number of subjects: 301
Study 29421974 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Cat and adapted GLTEQ measures
Number of subjects: 301
Study 29422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategy to improve guideline adherence, including a risk assessment checklist, care bundle, and time-out procedure.
Number of subjects: 0
Study 29422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment tools including a patient passport and a website with patient information.
Number of subjects: 0
Study 29422039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 12
Study 29422070 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 92
Study 29422070 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea values
Number of subjects: 92
Study 29422070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low urine osmolality
Number of subjects: 92
Study 29422070 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin and urea
Number of subjects: 92
Study 29422454 — intervention group
Group type: EXPERIMENTAL
Intervention: Do CHANGE service with Do Something Different (DSD) program to assist in changing unhealthy habits.
Number of subjects: 250
Study 29422454 — intervention group
Group type: EXPERIMENTAL
Intervention: Do CHANGE service with monitoring devices (Fitbit, Beddit, COOKiT, FLUiT) integrated in one application.
Number of subjects: 250
Study 29422724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subglottic suctioning (CSSS) at -20 mmHg
Number of subjects: 73
Study 29422724 — intervention group
Group type: COMPARATOR
Intervention: Intermittent subglottic suctioning (ISSS) at -100 mmHg
Number of subjects: 73
Study 29422881 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn activity tracking device providing multimodal feedback on daily arm use for 6 weeks
Number of subjects: 62
Study 29422881 — intervention group
Group type: COMPARATOR
Intervention: Identical device providing no feedback
Number of subjects: 62
Study 29423219 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (Cubitan, 20g protein taken orally 3 times a day for 6 months)
Number of subjects: 160
Study 29423219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (zero-protein ampule with identical instructions)
Number of subjects: 160
Study 29423259 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 30
Study 29423259 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 29423259 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 30
Study 29423515 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1) given intravenously every 3 weeks until unacceptable toxic effects, protocol nonadherence, or loss of clinical benefit.
Number of subjects: 95
Study 29424248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance therapy
Number of subjects: 0
Study 29424248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biomarker strategy for predicting incident HF
Number of subjects: 991
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Model without biomarkers
Number of subjects: 991
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with biomarkers
Number of subjects: 991
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for predicting incident HF
Number of subjects: 991
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal validation of the model
Number of subjects: 991
Study 29424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers
Number of subjects: 991
Study 29424677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublaminar band placement at the upper instrumented vertebra (UIV) plus 1 level (UIV+1) during long-segment thoracolumbar arthrodesis surgery.
Number of subjects: 40
Study 29424677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublaminar band placement at the UIV+1 during long-segment thoracolumbar arthrodesis surgery.
Number of subjects: 40
Study 29424775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen
Number of subjects: 27
Study 29425270 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI and resting-state functional MRI
Number of subjects: 0
Study 29426039 — intervention group
Group type: EXPERIMENTAL
Intervention: MRproANP
Number of subjects: 689
Study 29426039 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal proendothelin 1
Number of subjects: 689
Study 29426039 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 689
Study 29426039 — intervention group
Group type: EXPERIMENTAL
Intervention: Midregional-proadrenomedullin
Number of subjects: 689
Study 29426345 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement strategy involving community knowledge brokers
Number of subjects: 0
Study 29426345 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29426361 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic follow-up by nurses with three home visits over a period of 1 month.
Number of subjects: 48
Study 29426361 — intervention group
Group type: COMPARATOR
Intervention: Usual care guidelines of the health services (control group).
Number of subjects: 48
Study 29426380 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-Based Coaching via telehealth
Number of subjects: 18
Study 29426382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-wk activity program
Number of subjects: 0
Study 29426386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy and task-oriented training
Number of subjects: 4
Study 29426394 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized occupation-based diabetes management intervention
Number of subjects: 8
Study 29428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver demographic factors (self-reported black vs. white race and high school or less education vs. college or more)
Number of subjects: 868
Study 29428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's inability to get an immunization appointment as soon as needed
Number of subjects: 868
Study 29428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent's type of insurance
Number of subjects: 868
Study 29428177 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver or adolescent attitudes and beliefs about on-schedule HPV vaccination or HPV vaccine safety
Number of subjects: 868